PHARMA-FINANCE 2007. ROME 10-11 MAY

By Laura Teodori and Zofia Maciorowski

Rome, the eternal city, alongside its ancient ruins and classic architectural beauties, looks to the future. The title of this first Congress is thus ‘Pharma-Finance 2007 wagering on the future’. Promoted by Sviluppo Lazio (www.sviluppolazio.it) in collaboration with Zangani Investor Community (www.zangani.com) to foster interactions between drugs and biotech, innovative research enterprises and finance, in order to encourage growth opportunities: science, research and behind all this, industry and finance. Pharma-Finance 2007 was an important part of a program of internationalization policies with not just words and ideas but concrete advancement. The goal was to make Italian businesses and Lazio small and medium sized enterprises interact with equivalent US and international pharmaceutical and financial players.

From the Membership Services Committee of the International Society for Analytical Cytology
Laura Teodori and Zofia Maciorowski co-chairs

Dr. Claudio Panzarella ISAC Scholar and his mentor Prof. Laura Teodori

Pharma-Finance 2007. Rome 10-11 May

Rome, the eternal city, alongside its ancient ruins and classic architectural beauties, looks to the future. The title of this first Congress is thus ‘Pharma-Finance 2007 wagering on the future’. Promoted by Sviluppo Lazio (www.sviluppolazio.it) in collaboration with Zangani Investor Community (www.zangani.com) to foster interactions between drugs and biotech, innovative research enterprises and finance, in order to encourage growth opportunities: science, research and behind all this, industry and finance.

About C & O Pharmaceutical Technology (Holdings) Limited

Engages in research, manufacturing, marketing and distribution of C & O branded pharmaceutical products, as well as distribution of third party pharmaceutical products in all the provinces of China. Its manufacturing facilities are located in Nanjing. The company currently has a portfolio included 24 C & O-branded pharmaceutical products. C & O has an extensive distribution network covering approximately 3,000 distributors and over 300,000 clinics, pharmacies and hospitals and across the whole of China.

About Pharma Finance 2007

A unique two-day intensive approach to find and to offer, in an international environment: AIC, Patents & Licensing, Co-Marketing of Bio-Nano-Pharma Technologies. Pharma Finance 2007 is not an arena-style conference. It is specifically designed to support in-depth partnership development.

About Bradmer Pharmaceuticals

A biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. To date, over US$60 million in grants and related support has driven research and development of the licensed treatment, which has been delivered to over 200 patients with promising results and has completed Phase II clinical trials at Duke University. Bradmer is currently in the process of organizing a pivotal multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

About Pharma Finance 2007

A unique two-day intensive approach to find and to offer, in an international environment: AIC, Patents & Licensing, Co-Marketing of Bio-Nano-Pharma Technologies. Pharma Finance 2007 is not an arena-style conference. It is specifically designed to support in-depth partnership development.

About Manhattan Pharmaceuticals, Inc.

A development-stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for the treatment of both common obesity and morbid obesity. To meet the needs of other major, underserved medical markets Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for the treatment of psoriasis, and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures.

About Pharma Finance 2007

A unique two-day intensive approach to find and to offer, in an international environment: AIC, Patents & Licensing, Co-Marketing of Bio-Nano-Pharma Technologies. Pharma Finance 2007 is not an arena-style conference. It is specifically designed to support in-depth partnership development.

About SuperGen

A pharmaceutical company, based in Dublin, California, that is dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase.

About Pharma Finance 2007

A unique two-day intensive approach to find and to offer, in an international environment: AIC, Patents & Licensing, Co-Marketing of Bio-Nano-Pharma Technologies. Pharma Finance 2007 is not an arena-style conference. It is specifically designed to support in-depth partnership development.

About CytRx Corporation

A biopharmaceutical company engaged in the development of high-value therapeutics utilizing its core technologies in small molecule drugs, RNAi drug discovery and DNA vaccines. CytRx is developing products based on three unique platforms: small molecule chaperone amplification, RNAi technology, and DNA vaccines in a variety of therapeutic indications including ALS, obesity, type 2 diabetes, HIV and cardiovascular disease.

About Pharma Finance 2007

A unique two-day intensive approach to find and to offer, in an international environment: AIC, Patents & Licensing, Co-Marketing of Bio-Nano-Pharma Technologies. Pharma Finance 2007 is not an arena-style conference. It is specifically designed to support in-depth partnership development.

Cleveland BioLabs, Inc. (Nasdaq: CBLI - News; Boston Stock Exchange: CFB), today announced that the Company is scheduled to present at the Zangani Pharma Finance 2007 Conference to be held May 10-11, in Rome, Italy. The Company's presentation will be posted to http://www.zangani.com on May 16, and archived for a year.

In advance of the conference, Cleveland BioLabs President and Chief Executive, Officer Michael Fonstein, Ph.D. discussed the Company's background, recent developments and objectives for the Pharma Finance Conference with Zangani Investor Community. The interview may be accessed at: http://www.zangani.com/webcasts/20070427/cbli.

Dr. Jan H. Egberts Featured in Webcast Interview Regarding Event

NovaDel Pharma Inc. (AMEX: NVD - News), a specialty pharmaceutical company developing oral spray formulations of a broad range of marketed treatments, today announced that Dr. Jan H. Egberts, NovaDel's President and Chief Executive Officer, and Dr. Deni M. Zodda, NovaDel's Chief Business Officer and Senior Vice President, will attend the upcoming Pharma Finance 2007 Conference to be held in Rome, Italy on May 10 - 11, 2007. The Zangani Investor Community interviewed Dr. Egberts to discuss the Company's goals and objectives for the conference. The entire interview is available at: http://www.zangani.com/webcasts/20070419/nvd.

Zangani Investor Communityâ„¢ interviews Dr. Mark Rogers, Chairman and Chief Executive Officer of Bradmer Pharmaceuticals. Dr. Rogers discusses their upcoming presentation at our Pharma Finance 2007 conference in Rome, Italy on May 10th and 11th and their company business strategy.

Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme.

...Gastrointestinal Effects of Acute Radiation Syndrome

Department of Health and Human Services Announces Continued Pursuit of Acquisition of Medical Countermeasure to Treat Acute Radiation Syndrome

Cleveland BioLabs, Inc. (Nasdaq: CBLI; Boston Stock Exchange: CFB), today announced that it has responded to the Request for Proposal (RFP) issued in March 2007, by The Department of Defense (DoD) for the Advanced Development of Medical Radiation Countermeasures (MRC) to treat gastrointestinal effects of acute radiation syndrome (ARS). It is expected that the RFP may be awarded later in the year.

Zangani Investor Communityâ„¢ interviews Ms. LEE Ching Sze, Susana, Executive Director of C & O Pharmaceutical. Ms. LEE discusses their upcoming presentation at our Pharma Finance 2007 conference in Rome, Italy on May 10th and 11th and their company business strategy.

C & O Pharmaceutical Technology (Holdings) Limited (C & O) engages in research, manufacturing, marketing and distribution of C & O branded pharmaceutical products, as well as distribution of third party pharmaceutical products in all the provinces of China. Its manufacturing facilities are located in Nanjing. The company currently has a portfolio included 24 C & O-branded pharmaceutical products. C & O has an extensive distribution network covering approximately 3,000 distributors and over 300,000 clinics, pharmacies and hospitals and across the whole of China.